Company intelligence / Profile preview

Annovis Bio, Inc.

Malvern, Pennsylvania, USAannovisbio.com ↗

Ownership: Public · ANVS
Employees: ~15
Development stage: Phase 3

Overview

Buntanetap has shown statistically significant improvements in cognition in early Alzheimer’s patients and motor function in Parkinson's patients during Phase II/III trials. The FDA has cleared pivotal Phase III studies based on these results. No major safety concerns have been reported to date. The company aims to demonstrate both symptomatic and potential disease-modifying effects with ongoing large-scale trials.[6][8][10]

Therapeutic areas: Neurology
Modalities: Small molecules (notably oral small molecules such as buntanetap)[2][6]
Industry: Biotech

Drug pipeline

3 assets

buntanetap

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $50.6M
Total revenue: $0
Enterprise value: $31.9M

Beyond the preview

Go deeper on Annovis Bio, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Annovis Bio, Inc..

Explore the full profile